Posted by Michael Wonder on 05 Nov 2018
Aquestive Therapeutics announces U.S. FDA approval for Sympazan (clobazam) oral film
2 November 2018 - Sympazan is delivered via Aquestive's proprietary PharmFilm technology.
Aquestive Therapeutics today announced that the U.S. FDA approved Sympazan (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.
Sympazan is the first and only oral film FDA approved to treat seizures associated with LGS. Previously, clobazam was marketed as Onfi and offered in two formulations – either tablet or oral suspension.
